27例原发性食管小细胞癌的临床分析  

Clinical analysis of 27 patients with primary esophageal small-cell carcinoma

作　　者：潘雪峰 

机构地区：[1]解放军150中心医院肿瘤医院,河南洛阳471031

出　　处：《现代肿瘤医学》2013年第6期1254-1256,共3页Journal of Modern Oncology

摘　　要：目的:探讨原发性食管小细胞癌的临床特征、治疗和预后。方法:回顾性分析27例原发性食管小细胞癌的临床资料,分析影响预后的相关因素。结果:27例患者中混合型病理类型占22.2%(6/27),全组除3例患者仅接受单纯化疗外,其余患者均接受了手术或放疗联合化疗的综合治疗,27例患者总体中位生存期14.1个月(4.6-37.2个月),1年、2年及3年总生存率为65.3%、33.8%和9.7%。单因素分析提示临床分期、治疗方式为预后影响因素,多因素分析提示临床分期为影响预后的独立因素。结论:原发性食管小细胞癌可能起源于食管黏膜的多潜能干细胞,以化疗为主的综合治疗有望提高疗效。Objective：To investigate the clinical characteristics,therapy and prognosis of primary esophageal small-cell carcinoma（PESC）.Methods：The clinical data of 27 cases with PESC was analyzed retrospectively,The prognostic factors were analyzed.Results：The 22.2% patients had at least two pathological contents in 27 cases.All patients accepted combined therapy except 3 cases.The overall median survival time of these 27 cases was 14.1 months（4.6-37.2 months）.The 1-,2-and 3-year overall survival rates were 65.3%,33.8% and 9.7%,respectively.Univariate analysis revealed that the prognostic predictors included clinical stage and treatment modality.Multivariate analysis revealed that the clinical stage was independent prognostic factors of PESC.Conclusion：PESC maybe origin from multipotential stem cell.Chemotherapy combined with surgery and/or radiotherapy could be helpful in PESC patients.

关 键 词：食管肿瘤 小细胞癌 综合治疗 预后 

分 类 号：R735.1[医药卫生—肿瘤]